Clinical outcome at 2 years following diagnosis of medium chain acyl coenzyme a dehydrogenase deficiency through newborn screening: findings from the prospective UK collaborative and british paediatric surveillance unit studies

Abstract

BackgroundNewborn screening for medium chain acyl coenzyme A dehydrogenase deficiency (MCADD) has been implemented in a number of countries, including England (April 2009) but there are few reports of clinical outcome in large-scale prospective studies. During a UK pilot screening phase, all screen positive babies were followed through the British Paediatric Surveillance Unit (BPSU) to ascertain clinical outcome.AimTo report the spectrum of screen-positive MCADD referrals over a 2-year period and clinical outcomes at 2 years following confirmed MCADD diagnosis.MethodsBetween 1 March 2004 and 28 February 2006, 102 children were referred as presumptive positive (average triplicate screening C8 ≥0.5μmol/L) among 738 242 newborns screened at age 5–8 days (screen positive prevalence 1.4 per 10 000). Blood acylcarnitines, urine organic acids and c.985→G status, with extended mutation analysis in all non-c.985→G homozygotes (HMZ), were measured in all cases. Results were reviewed using an agreed diagnostic algorithm by an independent expert panel who assigned children to one of four categories: MCADD of definite phenotype; MCADD of uncertain phenotype; carriers; not MCADD. Clinician-reported clinical outcome at 1 and 2 years was obtained by systematic follow-up of new diagnoses notified to the BPSU.ResultsOf 102 screen positive infants (12 Asian; 43 female), 86 were confirmed as MCADD (positive predictive value 84%): 60 of definite phenotype (47 c.985→G HMZ, 13 other genotypes of known pathogenicity); 26 of uncertain phenotype (all with genotypes of uncertain pathogenicity). 79/86 (92%) were notified to the BPSU, with complete follow-up in 76 and partial follow up in three. At 2 years, one serious clinical episode was reported, one child experienced apnoea following vaccination and one child was reported with developmental delay/poor growth. One child (c.985→G HMZ) died after the 2-year follow-up period (age 2 years 9 months) during an intercurrent illness.ConclusionThe specificity of screening is high and prevalence of c.985A→G homozygosity (55%) is comparable to other international screening programmes. While clinical outcome among screened babies appears good, death can occur highlighting the importance of timely management of acute illnesses in children with MCADD and effective information for and education of parents. Further information on longer-term outcomes is needed.

“It’s Just Always Eating”: The Experiences of Young People Growing up Medium Chain Acyl-coA Dehydrogenase Deficiency

“…Over the past decade, screening for MCADD has been embedded into newborn screening programs in the United States of America, Canada, and many European countries including the UK (Jameson & Walter, 2019; Therrell et al, 2015). This has resulted in improved health outcomes because detecting the condition and instigating management in the first few days of life has significantly reduced the likelihood of adverse events including death (Lindner et al, 2011; Nennstiel-Ratzel et al, 2005; Oerton et al, 2010; Wilcken et al, 2009). MCADD is managed by diet, ensuring that food intake is sufficient to meet metabolic demands and avoiding prolonged periods of fasting.…”